Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Complete title: A Phase 1/1b Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15-15Ra)) alone and in Combination with PDR001 in Adults with Metastatic Cancers

Research Study Number 20170681
 
Principal Investigator John Thompson, MD
 
Phase I

Research Study Description

Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20170681
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Bladder Cancer; Esophageal Cancer; Gastrointestinal Cancer; Gynecological Cancer; Head and Neck Cancer; Prostate Cancer; Sarcoma; Solid Tumors; Colorectal Neoplasms; Esophageal Diseases; Gastrointestinal Diseases; Pathologic Processes; Neoplasm Metastasis; Advanced Solid Tumors; Metastatic Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials